Paladin Labs Inc. has announced the Canadian launch of Travelan, an over-the-counter product to help reduce the risk of travelers' diarrhea.


Paladin Labs, Travelan, travelers' diarrhea, over-the-counter product, Endo, Mark Beaudet, Enterotoxigenic escherichia coli bacteria, ETEC






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks

Paladin Labs launches Travelan in Canada

August 5th, 2014

MONTREAL – Paladin Labs Inc. has announced the Canadian launch of Travelan, an over-the-counter product to help reduce the risk of travelers' diarrhea.

The Endo International plc said Tuesday that Travelan is clinically proven to provide protection against the main cause of travelers' diarrhea in 90% of consumers who use it.

Travelan provides a convenient option for people traveling to at-risk regions such as Central and South America, Mexico, Africa, the Middle East and Asia, the company noted. The OTC medicine does not require a prescription and is not associated with any significant side effects.

An estimated 5 million-plus trips are made by Canadians to at-risk regions every year, Paladin reported. One-in-three Canadian vacationers have experienced, or have travelled with someone who has experienced, travelers' diarrhea. Sources of Enterotoxigenic escherichia coli (ETEC) bacteria, which cause the majority of cases of travelers' diarrhea, can include poorly cooked meat, contaminated raw vegetables or unpasteurized dairy products. Research shows that three-quarters of Canadians have indicated that they would take a preventive for travelers' diarrhea, according to the company.

A natural product, Travelan is designed to lower the risk of infection by ETEC. Paladin said that in clinical trials, Travelan showed efficacy of up to 90% in protecting against infection with the type of E.Coli that causes travellers' diarrhea. In addition, trials showed a significant reduction in abdominal cramps and stomach pain compared to those who did not receive Travelan. There were no reported treatment-related side effects in the clinical trials.

"We are pleased to announce the launch of Travelan in Canada," stated Mark Beaudet, president of Paladin Labs. "This option responds to the clear market need for a clinically proven, accessible option to help reduce the risk of travellers' diarrhea."

Paladin obtained the exclusive rights to market and sell Travelan in Canada, Latin America (including Brazil and Mexico) and Sub-Saharan Africa (including South Africa) from Immuron Ltd. in November 2011.

More Supplier News Breaks >>
Advertisement